Pembrolizumab, marketed as Keytruda, is an immunotherapy drug used to treat various types of cancer. It works by blocking a protein called PD-1, which prevents cancer cells from hiding from the immune system [1].
What types of cancer does Pembrolizumab treat?
Pembrolizumab is approved for the treatment of several cancers, including melanoma, non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma, classical Hodgkin lymphoma, and urothelial carcinoma [1]. It is also used for certain types of microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumors [1].
How does Pembrolizumab work to fight cancer?
Pembrolizumab is a type of checkpoint inhibitor. Cancer cells can express PD-L1, which binds to PD-1 receptors on T-cells, effectively switching off the immune response against the cancer [2]. Pembrolizumab binds to the PD-1 receptor, preventing this interaction and allowing T-cells to recognize and attack cancer cells [2].
When does Pembrolizumab's patent exclusivity expire?
Patent protection for drugs like Pembrolizumab is complex and can involve multiple patents covering different aspects of the drug, its manufacturing, and its uses [3]. Information on the specific patent expiry dates for Pembrolizumab can be found on resources like DrugPatentWatch.com [3]. For instance, general patent information related to pembrolizumab and its indications is publicly available.
What are the potential side effects of Pembrolizumab?
As with many immunotherapies, Pembrolizumab can cause side effects related to immune system activation. These can include inflammation in various organs such as the lungs (pneumonitis), colon (colitis), liver (hepatitis), and endocrine glands (thyroiditis, hypophysitis, adrenal insufficiency) [1]. Other common side effects include fatigue, rash, and diarrhea [1].
Are there biosimilar versions of Pembrolizumab in development?
The development of biosimilars for complex biologic drugs like Pembrolizumab is an ongoing process. Several companies are reportedly working on developing biosimilar versions of Pembrolizumab, which, if approved, could offer alternative treatment options [4]. The timeline for biosimilar market entry is often tied to patent expiry and regulatory approval processes.
How does Pembrolizumab compare to other cancer immunotherapies?
Pembrolizumab is one of several immune checkpoint inhibitors available. Other drugs in this class target similar pathways or different immune checkpoints, such as CTLA-4 inhibitors (e.g., ipilimumab) [2]. The choice of therapy depends on the specific cancer type, stage, and individual patient factors.
What is the cost of Pembrolizumab treatment?
The cost of Pembrolizumab treatment can be substantial, reflecting the expense associated with developing and manufacturing advanced biologic therapies. Actual costs can vary based on dosage, duration of treatment, insurance coverage, and geographic location [5].
Where can I find more detailed patent information for Pembrolizumab?
Detailed information regarding patents for Pembrolizumab, including their status and expiration dates, is available through specialized databases and services. DrugPatentWatch.com is a resource that tracks pharmaceutical patents and exclusivity periods for a wide range of drugs, including Pembrolizumab [3].
What are the latest clinical trial results for Pembrolizumab?
Ongoing clinical trials continue to evaluate Pembrolizumab's efficacy in various cancer types and combinations. Updates on clinical trial progress and results are regularly published in medical journals and presented at scientific conferences [6].
---
Sources:
[1] https://www.cancer.gov/about-cancer/treatment/drugs/pembrolizumab
[2] https://www.cancerresearch.org/about-cancer/treatment/types/immunotherapy/checkpoint-inhibitors
[3] https://drugpatentwatch.com/
[4] https://www.biosimilars-review.com/pembrolizumab-biosimilar/
[5] https://www.nejm.org/doi/full/10.1056/NEJMp1909478
[6] https://www.clinicaltrials.gov/ct2/results?recr=Open&cond=&term=pembrolizumab